PharVision Advisers’s MGP Ingredients MGPI Stock Holding History

PharVision Advisers’s Portfolio MGPI Stock Details MGPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,018	Closed	-$316K	–	423
2024 Q4	$316K	Buy	+8,018	New	+$436K	0.27%	135

Other funds holding MGPI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PharVision Advisers's MGPI Position: Q1 2025 in Review

PharVision Advisers sold out of MGP Ingredients (MGPI) in Q1 2025, closing a stake of 8,018 shares — an estimated $316K sold.

PharVision Advisers first reported a position in MGPI in Q4 2024 and held it in 1 quarter. The position peaked at $316K in Q4 2024. 200 funds tracked by Wall St. Rank hold MGPI as of Q1 2025.

PharVision Advisers reported no remaining MGP Ingredients position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 8,018 MGP Ingredients shares in Q1 2025, an estimated $316K.
PharVision Advisers first reported a position in MGP Ingredients in Q4 2024 and held it in 1 quarter.
PharVision Advisers's MGP Ingredients position peaked at $316K in Q4 2024.
200 funds tracked by Wall St. Rank held MGP Ingredients as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.